Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

229
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
229
Positron Emission Tomography01:29

Positron Emission Tomography

5.0K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sustainable Xanthine-Grafted Alginate Biosensing Platform for Metabolic Disorder Diagnostics.

ACS omega·2026
Same author

Picolinamide-functionalized macrocyclic chelators for <sup>203/212</sup>Pb theranostic radiotracers.

Inorganic chemistry frontiers·2026
Same author

In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.

Journal of the American Chemical Society·2026
Same author

Interpretive Reference Ranges for Plasma Drug Concentrations in Acute Recreational Drug Toxicity: A Short Communication.

Therapeutic drug monitoring·2026
Same author

Ion Beam Imaging Shows Selective Thallium-201 Uptake in Cell Nuclei: Impact on Cellular Dosimetry and Radiotoxicity of Auger Electron Emitters.

Chemical & biomedical imaging·2026
Same author

Multifunctional Halloysite-Glutathione Nanocomposite for Solar CO2 Conversion and Pollutant Sensing.

ACS applied nano materials·2026

Related Experiment Video

Updated: Sep 1, 2025

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.1K

Targeting integrin αvβ6 with gallium-68 tris (hydroxypyridinone) based PET probes.

Giuseppe Floresta1,2, Siham Memdouh1, Truc Pham3

  • 1King's College London, Institute of Pharmaceutical Science, Franklin Wilkins Building, London SE1 9NH, UK. agostino.cilibrizzi@kcl.ac.uk.

Dalton Transactions (Cambridge, England : 2003)
|August 16, 2022
PubMed
Summary

New positron emission tomography (PET) probes targeting αvβ6 integrin show high binding affinity. These probes facilitate in vivo monitoring of αvβ6 integrin in carcinomas, aiding tumor imaging and therapy.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

348
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K

Related Experiment Videos

Last Updated: Sep 1, 2025

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.1K
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

348
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.6K

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • αvβ6 integrin is a transmembrane receptor primarily expressed on malignant epithelial cells in various carcinomas.
  • Its restricted expression makes it a promising target for cancer imaging and therapy.

Purpose of the Study:

  • To develop and evaluate novel positron emission tomography (PET) probes for targeting αvβ6 integrin.
  • To assess the feasibility of using tris(3,4-hydroxypyridinone) (THP) chelators for rapid and stable gallium-68 (⁶⁸Ga) radiolabeling.

Main Methods:

  • Two ⁶⁸Ga-labeled THP chelators were synthesized and conjugated to an αvβ6 integrin-selective peptide (cyclo(FRGDLAFp(NMe)K)) via NHS chemistry.
  • Radiolabeling efficiency and binding affinities of the resulting PET probes were evaluated using cellular assays.

Main Results:

  • High radiochemical yields were achieved for both synthesized PET probes.
  • The probes demonstrated high binding affinities to αvβ6 integrin in the nanomolar range.
  • The THP chemistry enabled rapid, efficient, and stable chelation of ⁶⁸Ga.

Conclusions:

  • The developed integrin αvβ6-peptide-THP constructs are effective PET probes.
  • These probes show potential for in vivo monitoring of αvβ6 integrin expression in carcinomas.
  • The study highlights the utility of THP chemistry for developing targeted radiopharmaceuticals.